Adaptix Limited

Adaptix Limited specializes in advanced 3D X-ray technology, providing innovative point-of-use diagnostic imaging solutions that enhance the effectiveness and efficiency of radiological practices. Adaptix Limited is focused on developing 3D X-ray imaging solutions that integrate into current radiology settings. The company, headquartered in Oxford, UK, has received investment through multiple funding rounds, including a notable Buyout round in November 2019 where Par Equity acquired a 13. 5% minority stake for GBP 1.

57 million. The company's CEO is Sarah Small, who leads the firm in navigating its growth and product development strategy. Adaptix specializes in innovative 3D X-ray technology, offering point-of-use diagnostic imaging solutions designed to enhance the efficiency and effectiveness of radiological practices. Their core product integrates seamlessly into existing radiology environments, enabling routine 3D X-ray imaging that contributes to improved diagnostic assurance while reducing costs.

The company serves a diverse clientele, including healthcare providers in orthopaedics, veterinary practices, and chest imaging facilities, distributing its products not only in the UK but also in international markets like the Americas, EMEA, and APAC. In the most recent year, Adaptix reported a revenue of GBP 350,003 with an EBITDA loss of GBP 5,242,926. The company generates revenue primarily through direct sales and partnerships with healthcare providers, positioning its 3D X-ray systems as essential capital equipment for hospitals and clinics, supported by ongoing service agreements. Following the investment in November 2019, Adaptix plans to utilize the funds to enhance its product development and expand its market reach.

The company is developing new imaging solutions aimed at further diversifying its offerings, with an emphasis on penetrating additional geographic markets, particularly in the Americas and parts of EMEA before the end of 2024.